Skye Bioscience appoints Kaitlyn Arsenault as CFO, replacing interim Principal Accounting Officer

Skye Bioscience, Inc.

Punit Dhillon resigned as interim Principal Accounting Officer effective Oct 4, 2021; Kaitlyn Arsenault appointed CFO immediately.
Arsenault receives options for 1.6M shares at $0.09; 10% vest immediately, remainder over 4 years semi-annually.
Annual base salary $300k with discretionary bonus up to 35% of base; severance of 6 months' salary if terminated not for cause.
Arsenault has 14+ years experience in life science accounting, previously consultant to Skye for 6 years and Assurance Manager at Friedman LLP.
Skye is a biopharma developing cannabinoid-derived molecules for unmet medical needs; CFO appointment supports clinical program advancement.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Punit Dhillon

interim Principal Accounting Officer

SKYE · Skye Bioscience, Inc.

Effective: 2021-10-04
Successor: Kaitlyn Arsenault
Filed: October 6, 2021, 7:59 PM ET

As of October 4, 2021, Punit Dhillon has tendered his resignation from his position as the interim Principal Accounting Officer of Skye Bioscience, Inc. (the “Company”).

Appointed

Kaitlyn Arsenault

Chief Financial Officer

SKYE · Skye Bioscience, Inc.

Effective: 2021-10-04
Filed: October 6, 2021, 7:59 PM ET

On October 4, 2021, the Board of Directors of the Company (the “Board”) appointed Kaitlyn Arsenault as the new Chief Financial Officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Punit Dhillon resigned as interim Principal Accounting Officer at Skye Bioscience, Inc..

Action: resigned
Role: interim Principal Accounting Officer

Exact text from the filing

As of October 4, 2021, Punit Dhillon has tendered his resignation from his position as the interim Principal Accounting Officer of Skye Bioscience, Inc. (the “Company”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kaitlyn Arsenault was appointed as Chief Financial Officer at Skye Bioscience, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On October 4, 2021, the Board of Directors of the Company (the “Board”) appointed Kaitlyn Arsenault as the new Chief Financial Officer of the Company, effective immediately.

View on SEC.gov

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001516551-21-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.